Delivery Order SPE2DR25D9113-SPE2DR26FCHT6

The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,783.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of YF-VAX (Yellow Fever Vaccine) in 1-dose vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of December 18, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA—the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.

The PPV-G GEN V represents a major strategic acquisition vehicle within the Department of Defense's pharmaceutical supply chain, designed to provide military healthcare facilities worldwide with comprehensive pharmaceutical and medical consumable support. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under this $30.3 billion initiative, authorized to fulfill diverse and specialized pharmaceutical requirements for DoD medical operations. As a critical supplier within the federal pharmaceutical supply chain with demonstrated performance across multiple therapeutic categories—including vaccines, biologics, specialty pharmaceuticals, and routine medications—DMS Pharmaceutical Group has maintained consistent contract performance on numerous DLA delivery orders since October 2025, with individual awards ranging substantially in value to support recurring military medical supply needs.